Krebs Biochemicals And Stock Current Valuation
| KREBSBIO | 85.12 0.06 0.07% |
Valuation analysis of Krebs Biochemicals and helps investors to measure Krebs Biochemicals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of now, Krebs Biochemicals' Other Non Cash Items is increasing as compared to previous years. The Krebs Biochemicals' current Total Cash From Operating Activities is estimated to increase to about 24.2 M, while Cash is projected to decrease to under 1.3 M. Fundamental drivers impacting Krebs Biochemicals' valuation include:
Enterprise Value 4.2 B | Enterprise Value Ebitda (16.12) | Price Sales 3.5737 | Enterprise Value Revenue 8.3938 |
Fairly Valued
Today
Please note that Krebs Biochemicals' price fluctuation is very steady at this time. Calculation of the real value of Krebs Biochemicals and is based on 3 months time horizon. Increasing Krebs Biochemicals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Krebs Biochemicals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Krebs Stock. However, Krebs Biochemicals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 85.12 | Real 86.29 | Hype 85.25 | Naive 81.17 |
The intrinsic value of Krebs Biochemicals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Krebs Biochemicals' stock price.
Estimating the potential upside or downside of Krebs Biochemicals and helps investors to forecast how Krebs stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Krebs Biochemicals more accurately as focusing exclusively on Krebs Biochemicals' fundamentals will not take into account other important factors: Krebs Biochemicals and Company Current Valuation Analysis
Krebs Biochemicals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Krebs Biochemicals Current Valuation | 4.23 B |
Most of Krebs Biochemicals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Krebs Biochemicals and is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Krebs Biochemicals and has a Current Valuation of 4.23 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all India stocks is notably lower than that of the firm.
Krebs Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Krebs Biochemicals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Krebs Biochemicals could also be used in its relative valuation, which is a method of valuing Krebs Biochemicals by comparing valuation metrics of similar companies.Krebs Biochemicals is currently under evaluation in current valuation category among its peers.
Krebs Fundamentals
| Return On Asset | -0.0532 | ||||
| Profit Margin | (0.37) % | ||||
| Operating Margin | (0.30) % | ||||
| Current Valuation | 4.23 B | ||||
| Shares Outstanding | 21.56 M | ||||
| Shares Owned By Insiders | 77.55 % | ||||
| Price To Sales | 3.57 X | ||||
| Revenue | 504.21 M | ||||
| Gross Profit | 244.19 M | ||||
| EBITDA | (82.73 M) | ||||
| Net Income | (197.28 M) | ||||
| Cash And Equivalents | (1 K) | ||||
| Total Debt | 1.93 B | ||||
| Book Value Per Share | (55.29) X | ||||
| Cash Flow From Operations | 23.04 M | ||||
| Earnings Per Share | (9.09) X | ||||
| Number Of Employees | 191 | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 1.85 B | ||||
| Total Asset | 1.78 B | ||||
| Retained Earnings | (2.7 B) | ||||
| Working Capital | (443.92 M) | ||||
| Net Asset | 1.78 B |
About Krebs Biochemicals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Krebs Biochemicals and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Krebs Biochemicals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Krebs Biochemicals and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Krebs Stock
Krebs Biochemicals financial ratios help investors to determine whether Krebs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Krebs with respect to the benefits of owning Krebs Biochemicals security.